By Fineline Cube Astellas Pharma Inc. (TYO: 4503) announced that it has submitted a New Drug Application (NDA) to Japan’s Ministry of Health, Labour and Welfare (MHLW) seeking approval of fezolinetant, a neurokinin 3 (NK3) receptor antagonist, for the treatment of vasomotor symptoms (VMS) — also known as hot flushes and sweating — associated with menopause.
Regulatory Submission Overview
| Item | Detail |
|---|---|
| Applicant | Astellas Pharma Inc. (TYO: 4503) |
| Regulatory Agency | Ministry of Health, Labour and Welfare (MHLW), Japan |
| Submission Type | New Drug Application (NDA) |
| Product | Fezolinetant (NK3 receptor antagonist) |
| Indication | Vasomotor symptoms (VMS / hot flushes and sweating) associated with menopause |
| Submission Date | 7 Aug 2026 |
| Potential Distinction | First nonhormonal treatment in Japan targeting the NK3 receptor pathway for menopausal VMS |
Supporting Clinical Evidence
| Evidence Source | Role in Submission |
|---|---|
| Two Phase 3 STARLIGHT Studies | Pivotal data conducted in Japanese women with VMS associated with menopause |
| Additional Japan Clinical Studies | Supplementary data supporting the NDA package |
| Global Clinical Development Program | Provides supportive context for the overall safety and efficacy profile |
The submission package is anchored by the two Phase 3 STARLIGHT studies in Japanese women, supplemented by broader data from Astellas’ global clinical development program for fezolinetant.
Drug Profile & Mechanism of Action
- Molecule: Fezolinetant
- Class: NK3 receptor antagonist — a nonhormonal mechanism of action
- Mechanism: Targets the NK3 receptor pathway implicated in the thermoregulatory dysfunction underlying menopausal hot flushes and sweating
- Differentiation: If approved, fezolinetant would be the first nonhormonal treatment option in Japan to target the NK3 receptor pathway for women experiencing VMS associated with menopause
Strategic Rationale & Market Impact
- Nonhormonal Gap in Japan: Many menopausal women cannot or choose not to use hormone therapy; a nonhormonal option addressing VMS fills a significant unmet need in the Japanese market.
- First‑Mover Positioning: As the first NK3 receptor‑targeted therapy for VMS in Japan, fezolinetant would establish a new therapeutic class, with associated pricing and market‑share advantages.
- Portfolio Synergy: The filing reinforces Astellas’ commitment to women’s health and strengthens the company’s late‑stage pipeline in Japan, its home market.
- Global Evidence Base: Data from the international clinical development program provide supportive context that may facilitate regulatory confidence and future label discussions.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the regulatory review timeline, approval outcome, and commercial potential of fezolinetant in Japan. Actual results may differ due to risks including regulatory decisions, clinical interpretations, and competitive dynamics.-Fineline Info & Tech